Phase 2 study in a bleeding disorder
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs ALN 6400 (Primary)
- Indications Blood coagulation disorders
- Focus Therapeutic Use
- 15 Jan 2025 New trial record
- 12 Jan 2025 According to Alnylam Pharmaceuticals media release, company to initiate a Phase 2 study in a bleeding disorder in the second half of 2025.